CEL-SCI slides after pricing $2.5M best-efforts stock offering at $1.00/share

What's the deal? CEL-SCIDealroom has a profile for this one. Try Dealroom → Corporation (CVM) has priced a $2.5M best-efforts public offering of 2.5 million shares of common stock at $1.00 per share. The stock slid 7.4% in premarket trading following the announcement.

The company expects $2.5M in gross proceeds before placement agent fees and other expenses.

What could go wrong? The offering is structured on a "best-efforts" basis, meaning the placement agent has no obligation to buy any shares it cannot sell — offering no guarantee the full amount will be raised. The steep discount implied by the premarket drop suggests investors see the dilution as a warning sign rather than a growth catalyst.

At $1.00 per share, the pricing signals limited leverage in negotiations with investors, which could weigh on the stock further.

The signal: Small-cap biotech firms like CEL-SCI continue to face a punishing funding environment. When companies resort to deeply discounted, best-efforts offerings of this size, it typically reflects difficulty accessing capital through more favourable channels. For investors, these micro-raises are often a red flag about runway and near-term prospects.

Read more: Seeking Alpha